The incidence of severe valvular dysfunctions (e.g., stenosis and insufficiency) is increasing, leading to over 300,000 valves implanted worldwide yearly. Clinically used heart valve replacements lack the capacity to grow, inherently requiring repetitive and high-risk surgical interventions during childhood. The aim of this review is to present how different tissue engineering strategies can overcome these limitations, providing innovative valve replacements that proved to be able to integrate and remodel in pre-clinical experiments and to have promising results in clinical studies. Upon description of the different types of heart valve tissue engineering (e.g., in vitro, in situ, in vivo, and the pre-seeding approach) we focus on the clinical translation of this technology. In particular, we will deepen the many technical, clinical, and regulatory aspects that need to be solved to endure the clinical adaptation and the commercialization of these promising regenerative valves.

Keywords:
Heart valves, Heart valve prosthesis, Tissue engineering, Transcatheter aortic valve replacement, Scaffolds, Regenerative medicine, Decellularized tissues, Biomaterials
1.
Manji RA, Ekser B, Menkis AH, Cooper DK: Bioprosthetic heart valves of the future. Xenotransplantation 2014;21:1-10.
2.
Prosthetic heart valve market by type (mechanical, transcatheter, tissue), and geography (Americas, Europe, Asia-Pacific, Middle East & Africa) - global forecast to 2020. www.marketsandmarkets.com/Market-Reports/prosthetic-heart-valve-market-245407958.html (last accessed July 6, 2016).
3.
Soliman Hamad MA, van Eekelen E, van Agt T, van Straten AH: Self-management program improves anticoagulation control and quality of life: a prospective randomized study. Eur J Cardiothorac Surg 2009;35:265-269.
4.
Alsoufi B: Aortic valve replacement in children: options and outcomes. J Saudi Heart Assoc 2014;26:33-41.
5.
Brown ML, McKellar SH, Sundt TM, Schaff HV: Ministernotomy versus conventional sternotomy for aortic valve replacement: a systematic review and meta-analysis. J Thorac Cardiovasc Surg 2009;137:670-679.e5.
6.
Schoen FJ, Gotlieb AI: Heart valve health, disease, replacement, and repair: a 25-year cardiovascular pathology perspective. Cardiovasc Pathol 2016;25:341-352.
7.
Luk A, Rao V, Cusimano RJ, David TE, Butany J: Cormatrix extracellular matrix used for valve repair in the adult: is there de novo valvular tissue seen? Ann Thorac Surg 2015;99:2205-2207.
8.
Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, Derumeaux G, Anselme F, Laborde F, Leon MB: Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: First human case description. Circulation 2002;106:3006-3008.
9.
Rabkin-Aikawa E, Mayer JE, Schoen FJ: Heart valve regeneration. Adv Biochem Eng Biotechnol 2005;94:141-179.
10.
Mendelson K, Schoen FJ: Heart valve tissue engineering: concepts, approaches, progress, and challenges. Ann Biomed Eng 2006;34:1799-1819.
11.
Langer R, Vacanti JP: Tissue engineering. Science 1993;260:920-926.
12.
Tedder ME, Simionescu A, Chen J, Liao J, Simionescu DT: Assembly and testing of stem cell-seeded layered collagen constructs for heart valve tissue engineering. Tissue Eng Part A 2011;17:25-36.
13.
Kasimir MT, Rieder E, Seebacher G, Silberhumer G, Wolner E, Weigel G, Simon P: Comparison of different decellularization procedures of porcine heart valves. Int J Artif Organs 2003;26:421-427.
14.
Cheung DY, Duan B, Butcher JT: Current progress in tissue engineering of heart valves: multiscale problems, multiscale solutions. Expert Opin Biol Ther 2015;15:1155-1172.
15.
van Loon SLM, Smits AIPM, Driessen-Mol A, Baaijens FPT, Bouten CVC: The immune response in in situ tissue engineering of aortic heart valves; in Aikawa E (ed): Calcific Aortic Valve Disease. Rijeka, InTech, 2013, pp 207-245.
16.
Bouten CV, Dankers PY, Driessen-Mol A, Pedron S, Brizard AM, Baaijens FP: Substrates for cardiovascular tissue engineering. Adv Drug Deliv Rev 2011;63:221-241.
17.
Rieder E, Kasimir MT, Silberhumer G, Seebacher G, Wolner E, Simon P, Weigel G: Decellularization protocols of porcine heart valves differ importantly in efficiency of cell removal and susceptibility of the matrix to recellularization with human vascular cells. J Thorac Cardiovasc Surg 2004;127:399-405.
18.
Dohmen PM, Lembcke A, Holinski S, Kivelitz D, Braun JP, Pruss A, Konertz W: Mid-term clinical results using a tissue-engineered pulmonary valve to reconstruct the right ventricular outflow tract during the ross procedure. Ann Thorac Surg 2007;84:729-736.
19.
Hoerstrup SP, Kadner A, Melnitchouk S, Trojan A, Eid K, Tracy J, Sodian R, Visjager JF, Kolb SA, Grunenfelder J, Zund G, Turina MI: Tissue engineering of functional trileaflet heart valves from human marrow stromal cells. Circulation 2002;106(12 suppl 1):I143-I150.
20.
Schmidt D, Achermann J, Odermatt B, Breymann C, Mol A, Genoni M, Zund G, Hoerstrup SP: Prenatally fabricated autologous human living heart valves based on amniotic fluid derived progenitor cells as single cell source. Circulation 2007;116(11 suppl):I64-I70.
21.
Sales VL, Mettler BA, Engelmayr GC, Aikawa E, Bischoff J, Martin DP, Exarhopoulos A, Moses M, Schoen FJ, Sacks M, Mayer J: Endothelial progenitor cells as a sole source for ex vivo seeding of tissue-engineered heart valves. Tissue Eng Part A. 2010;16:257-267.
22.
Sodian R, Schaefermeier P, Begg-Zips S, Kuebler WM, Shakibaei M, Daebritz S, Ziegelmueller J, Schmitz C, Reichart B: Use of human umbilical cord blood-derived progenitor cells for tissue-engineered heart valves. Ann Thorac Surg 2010;89:819-828.
23.
Frese L, Sanders B, Beer GM, Weber B, Driessen-Mol A, Baaijens FPT, Hoerstrup SP: Adipose derived tissue engineered heart valve. J Tissue Sci Eng 2015;6:156.
24.
Lichtenberg A, Tudorache I, Cebotari S, Suprunov M, Tudorache G, Goerler H, Park JK, Hilfiker-Kleiner D, Ringes-Lichtenberg S, Karck M, Brandes G, Hilfiker A, Haverich A: Preclinical testing of tissue-engineered heart valves re-endothelialized under simulated physiological conditions. Circulation 2006;114(1 suppl): I559-I565.
25.
Iop L, Renier V, Naso F, Piccoli M, Bonetti A, Gandaglia A, Pozzobon M, Paolin A, Ortolani F, Marchini M, Spina M, De Coppi P, Sartore S, Gerosa G: The influence of heart valve leaflet matrix characteristics on the interaction between human mesenchymal stem cells and decellularized scaffolds. Biomaterials 2009;30:4104-4116.
26.
Mol A, Driessen NJ, Rutten MC, Hoerstrup SP, Bouten CV, Baaijens FP: Tissue engineering of human heart valve leaflets: a novel bioreactor for a strain-based conditioning approach. Ann Biomed Eng 2005;33:1778-1788.
27.
Del Gaudio C, Bianco A, Grigioni M: Electrospun bioresorbable trileaflet heart valve prosthesis for tissue engineering: in vitro functional assessment of a pulmonary cardiac valve design. Ann Ist Super Sanita 2008;44:178-186.
28.
Sodian R, Hoerstrup SP, Sperling JS, Daebritz SH, Martin DP, Schoen FJ, Vacanti JP, Mayer JEJ: Tissue engineering of heart valves: in vitro experiences. Ann Thorac Surg 2000;70:140-144.
29.
Hoerstrup SP, Sodian R, Daebritz S, Wang J, Bacha EA, Martin DP, Moran AM, Guleserian KJ, Sperling JS, Kaushal S, Vacanti JP, Schoen FJ, Mayer JE Jr: Functional living trileaflet heart valves grown in vitro. Circulation 2000;102(19 suppl 3):III44-49.
30.
Robinson PS, Johnson SL, Evans MC, Barocas VH, Tranquillo RT: Functional tissue-engineered valves from cell-remodeled fibrin with commissural alignment of cell-produced collagen. Tissue Eng Part A 2008;14:83-95.
31.
Gottlieb D, Kunal T, Emani S, Aikawa E, Brown DW, Powell AJ, Nedder A, Engelmayr GC, Jr., Melero-Martin JM, Sacks MS, Mayer JE Jr: In vivo monitoring of function of autologous engineered pulmonary valve. J Thorac Cardiovasc Surg 2010;139:723-731.
32.
Flanagan TC, Sachweh JS, Frese J, Schnöring H, Gronloh N, Koch S, Tolba RH, Schmitz-Rode T, Jockenhoevel S: In vivo remodeling and structural characterization of fibrin-based tissue-engineered heart valves in the adult sheep model. Tissue Eng Part A 2009;15:2965-2976.
33.
Schmidt D, Dijkman PE, Driessen-Mol A, Stenger R, Mariani C, Puolakka A, Rissanen M, Deichmann T, Odermatt B, Weber B, Emmert MY, Zund G, Baaijens FP, Hoerstrup SP: Minimally-invasive implantation of living tissue engineered heart valves: a comprehensive approach from autologous vascular cells to stem cells. J Am Coll Cardiol 2010;56:510-520.
34.
Stock UA, Nagashima M, Khalil PN, Nollert GD, Herden T, Sperling JS, Moran A, Lien J, Martin DP, Schoen FJ, Vacanti JP, Mayer JEJ: Tissue-engineered valved conduits in the pulmonary circulation. J Thorac Cardiovasc Surg 2000;119:732-740.
35.
Sutherland FWH, Perry TE, Yu Y, Sherwood MC, Rabkin E, Masuda Y, Garcia GA, McLellan DL, Engelmayr GCJ, Sacks MS, Schoen FJ, Mayer JEJ: From stem cells to viable autologous semilunar heart valve. Circulation 2005;111:2783-2791.
36.
Syedain Z, Reimer J, Schmidt J, Lahti M, Berry J, Bianco R, Tranquillo RT: 6-month aortic valve implantation of an off-the-shelf tissue-engineered valve in sheep. Biomaterials 2015;73:175-184.
37.
Shinoka T, Breuer CK, Tanel RE, Zund G, Miura T, Ma PX, Langer R, Vacanti JP, Mayer JE Jr: Tissue engineering heart valves: valve leaflet replacement study in a lamb model. Ann Thorac Surg 1995;60(6 suppl): S513-516.
38.
Steinhoff G, Stock U, Karim N, Mertsching H, Timke A, Meliss RR, Pethig K, Haverich A, Bader A: Tissue engineering of pulmonary heart valves on allogenic acellular matrix conduits: in vivo restoration of valve tissue. Circulation 2000;102(19 suppl 3):III50-III55.
39.
Dijkman PE, Driessen-Mol A, de Heer LM, Kluin J, van Herwerden LA, Odermatt B, Baaijens FP, Hoerstrup SP: Trans-apical versus surgical implantation of autologous ovine tissue-engineered heart valves. J Heart Valve Dis 2012;21:670-678.
40.
Jordan JE, Williams JK, Lee SJ, Raghavan D, Atala A, Yoo JJ: Bioengineered self-seeding heart valves. J Thorac Cardiovasc Surg 2012;143:201-208.
41.
Honge JL, Funder J, Hansen E, Dohmen PM, Konertz W, Hasenkam JM: Recellularization of aortic valves in pigs. Eur J Cardiothorac Surg 2011;39:829-834.
42.
Ota T, Taketani S, Iwai S, Miyagawa S, Furuta M, Hara M, Uchimura E, Okita Y, Sawa Y: Novel method of decellularization of porcine valves using polyethylene glycol and gamma irradiation. Ann Thorac Surg 2007;83:1501-1507.
43.
Dijkman PE, Driessen-Mol A, Frese L, Hoerstrup SP, Baaijens FP: Decellularized homologous tissue-engineered heart valves as off-the-shelf alternatives to xeno- and homografts. Biomaterials 2012;33:4545-4554.
44.
Driessen-Mol A, Emmert MY, Dijkman PE, Frese L, Sanders B, Weber B, Cesarovic N, Sidler M, Leenders J, Jenni R, Grunenfelder J, Falk V, Baaijens FP, Hoerstrup SP: Transcatheter implantation of homologous ‘off-the-shelf' tissue-engineered heart valves with self-repair capacity: long-term functionality and rapid in vivo remodeling in sheep. J Am Coll Cardiol 2014;63:1320-1329.
45.
Weber B, Dijkman PE, Scherman J, Sanders B, Emmert MY, Grunenfelder J, Verbeek R, Bracher M, Black M, Franz T, Kortsmit J, Modregger P, Peter S, Stampanoni M, Robert J, Kehl D, van Doeselaar M, Schweiger M, Brokopp CE, Walchli T, Falk V, Zilla P, Driessen-Mol A, Baaijens FP, Hoerstrup SP: Off-the-shelf human decellularized tissue-engineered heart valves in a non-human primate model. Biomaterials 2013;34:7269-7280.
46.
Reimer JM, Syedain ZH, Haynie BH, Tranquillo RT: Pediatric tubular pulmonary heart valve from decellularized engineered tissue tubes. Biomaterials 2015;62:88-94.
47.
Mol A, Smits A, Bouten C, Baaijens F: Tissue engineering of heart valves: advances and current challanges. Expert Rev Med Devices 2009;6:259-275.
48.
Latif N, Sarathchandra P, Thomas PS, Antoniw J, Batten P, Chester AH, Taylor PM, Yacoub MH: Characterization of structural and signaling molecules by human valve interstitial cells and comparison to human mesenchymal stem cells. J Heart Valve Dis 2007;16:56-66.
49.
Hashi CK, Zhu Y, Yang GY, Young WL, Hsiao BS, Wang K, Chu B, Li S: Antithrombogenic property of bone marrow mesenchymal stem cells in nanofibrous vascular grafts. Proc Natl Acad Sci U S A 2007;104:11915-11920.
50.
Uccelli A, Moretta L, Pistoia V: Immunoregulatory function of mesenchymal stem cells. Eur J Immunol 2006;36:2566-2573.
51.
Mirza A, Hyvelin JM, Rochefort GY, Lermusiaux P, Antier D, Awede B, Bonnet P, Domenech J, Eder V: Undifferentiated mesenchymal stem cells seeded on a vascular prosthesis contribute to the restoration of a physiologic vascular wall. J Vasc Surg 2008;47:1313-1321.
52.
Pittenger MF, Martin BJ: Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res 2004;95:9-20.
53.
Roh JD, Sawh-Martinez R, Brennan MP, Jay SM, Devine L, Rao DA, Yi T, Mirensky TL, Nalbandian A, Udelsman B, Hibino N, Shinoka T, Saltzman WM, Snyder E, Kyriakides TR, Pober JS, Breuer CK: Tissue-engineered vascular grafts transform into mature blood vessels via an inflammation-mediated process of vascular remodeling. Proc Natl Acad Sci U S A 2010;107:4669-4674.
54.
Hayashida K, Kanda K, Oie T, Okamoto Y, Ishibashi-Ueda H, Onoyama M, Tajikawa T, Ohba K, Yaku H, Nakayama Y: Architecture of an in vivo-tissue engineered autologous conduit ‘biovalve'. J Biomed Mater Res B Appl Biomater 2008;86:1-8.
55.
Sumikura H, Nakayama Y, Ohnuma K, Kishimoto S, Takewa Y, Tatsumi E: In vitro hydrodynamic evaluation of a biovalve with stent (tubular leaflet type) for transcatheter pulmonary valve implantation. J Artif Organs 2015;18:307-314.
56.
Kishimoto S, Takewa Y, Nakayama Y, Date K, Sumikura H, Moriwaki T, Nishimura M, Tatsumi E: Sutureless aortic valve replacement using a novel autologous tissue heart valve with stent (stent biovalve): proof of concept. J Artif Organs 2015;18:185-190.
57.
Nakayama Y, Kaneko Y, Takewa Y, Okumura N: Mechanical properties of human autologous tubular connective tissues (human biotubes) obtained from patients undergoing peritoneal dialysis. J Biomed Mater Res B Appl Biomater 2015; doi: 10.1002/jbm.b.33495.
58.
Dohmen PM, Lembcke AH, Hotz H, Kivelitz D, Konertz WF: Ross operation with a tissue-engineered heart valve. Ann Thorac Surg 2002;74:1438-1442.
59.
Dohmen PM, Lembcke A, Holinski S, Pruss A, Konertz W: Ten years of clinical results with a tissue-engineered pulmonary valve. Ann Thorac Surg 2011;92:1308-1314.
60.
Cebotari S, Lichtenberg A, Tudorache I, Hilfiker A, Mertsching H, Leyh R, Breymann T, Kallenbach K, Maniuc L, Batrinac A, Repin O, Maliga O, Ciubotaru A, Haverich A: Clinical application of tissue engineered human heart valves using autologous progenitor cells. Circulation 2006;114(1 suppl):I132-137.
61.
Gui L, Chan SA, Breuer CK, Niklason LE: Novel utilization of serum in tissue decellularization. Tissue Eng Part C Methods 2010;16:173-184.
62.
Cebotari S, Tudorache I, Ciubotaru A, Boethig D, Sarikouch S, Goerler A, Lichtenberg A, Cheptanaru E, Barnaciuc S, Cazacu A, Maliga O, Repin O, Maniuc L, Breymann T, Haverich A: Use of fresh decellularized allografts for pulmonary valve replacement may reduce the reoperation rate in children and young adults: Early report. Circulation 2011;124(11 suppl):S115-123.
63.
Sarikouch S, Horke A, Tudorache I, Beerbaum P, Westhoff-Bleck M, Boethig D, Repin O, Maniuc L, Ciubotaru A, Haverich A, Cebotari S: Decellularized fresh homografts for pulmonary valve replacement: A decade of clinical experience. Eur J Cardiothorac Surg 2016; doi: 10.1093/ejcts/ezw050.
64.
Simon P, Kasimir MT, Seebacher G, Weigel G, Allrich R, Salzer-Muhar U, Rieder E, Wolner E: Early failure of the tissue engineered porcine heart valve synergraft in pediatric patients. Eur J Cardiothorac Surg 2003;23:1002-1006.
65.
Voges I, Brasen JH, Entenmann A, Scheid M, Scheewe J, Fischer G, Hart C, Andrade A, Pham HM, Kramer HH, Rickers C: Adverse results of a decellularized tissue-engineered pulmonary valve in humans assessed with magnetic resonance imaging. Eur J Cardiothorac Surg 2013;44:e272-279.
66.
Ruffer A, Purbojo A, Cicha I, Glockler M, Potapov S, Dittrich S, Cesnjevar RA: Early failure of xenogenous de-cellularised pulmonary valve conduits-a word of caution! Eur J Cardiothorac Surg 2010;38:78-85.
67.
Woo JS, Fishbein MC, Reemtsen B: Histologic examination of decellularized porcine intestinal submucosa extracellular matrix (cormatrix) in pediatric congenital heart surgery. Cardiovasc Pathol 2015;25:12—17.
68.
Human P, Zilla P: Characterization of the immune response to valve bioprostheses and its role in primary tissue failure. Ann Thorac Surg 2001;71(5 suppl):S385-S388.
69.
Balguid A, Mol A, van Marion MH, Bank RA, Bouten CVC, Baaijens FPT: Tailoring fiber diameter in electrospun poly(epsilon-caprolactone) scaffolds for optimal cellular infiltration in cardiovascular tissue engineering. Tissue Eng Part A 2009;15:437-444.
70.
Schmidt B, Spriestersbach H, O H-Ici D, Radtke T, Bartosch M, Peters H, Sigler M, Frese L, Dijkman P, Baaijens F, Hoerstrup SP, Berger F: Percutaneous pulmonary valve replacement using completely tissue-engineered off-the-shelf heart valves: six-month in vivo functionality and matrix remodelling in sheep. EuroIntervention 2016;12:62-70.
71.
Emmert MY, Weber B, Behr L, Sammut S, Frauenfelder T, Wolint P, Scherman J, Bettex D, Grunenfelder J, Falk V, Hoerstrup SP: Transcatheter aortic valve implantation using anatomically oriented, marrow stromal cell-based, stented, tissue-engineered heart valves: technical considerations and implications for translational cell-based heart valve concepts. Eur J Cardiothorac Surg 2014;45:61-68.
72.
Soares JS, Moore JE Jr: Biomechanical challenges to polymeric biodegradable stents. Ann Biomed Eng 2016;44:560-579.
73.
Brown BN, Valentin JE, Stewart-Akers AM, McCabe GP, Badylak SF: Macrophage phenotype and remodeling outcomes in response to biologic scaffolds with and without a cellular component. Biomaterials 2009;30:1482-1491.
74.
Gallo M, Bonetti A, Poser H, Naso F, Bottio T, Bianco R, Paolin A, Franci P, Busetto R, Frigo AC, Buratto E, Spina M, Marchini M, Ortolani F, Iop L, Gerosa G: Decellularized aortic conduits: Could their cryopreservation affect post-implantation outcomes? A morpho-functional study on porcine homografts. Heart Vessels 2016; DOI 10.1007/s00380-016-0839-5.
75.
Brockbank KGM: Effects of cryopreservation upon vein function in vivo. Cryobiology 1994;31:71-81.
76.
Song YC, Khirabadi BS, Lightfoot F, Brockbank KGM, Taylor MJ: Vitreous cryopreservation maintains the function of vascular grafts. Nat Biotech 2000;18:296-299.
77.
Wang S, Goecke T, Meixner C, Haverich A, Hilfiker A, Wolkers WF: Freeze-dried heart valve scaffolds. Tissue Eng Part C Methods 2012;18:517-525.
78.
Brockbank KGM: Tissue Engineering Constructs and Commercialization. Austin, Landes Bioscience, 2000.
79.
Iso 13485:2016: Medical Devices - Quality Management Systems -Requirements for Regulatory Purposes.
80.
Iso 10993-13:2010: Biological Evaluation of Medical Devices - Part 13: Identification and Quantification of Degradation Products from Polymeric Medical Devices.
81.
Iso 5840-1:2015: Cardiovascular Implants - Cardiac Valve Prostheses - Part 1: General Requirements.
82.
Shinoka T, Ma PX, Shum-Tim D, Breuer CK, Cusick RA, Zund G, Langer R, Vacanti JP, Mayer JE Jr: Tissue-engineered heart valves. Autologous valve leaflet replacement study in a lamb model. Circulation 1996;94(9 suppl):II164-168.
83.
Weber B, Scherman J, Emmert MY, Gruenenfelder J, Verbeek R, Bracher M, Black M, Kortsmit J, Franz T, Schoenauer R, Baumgartner L, Brokopp C, Agarkova I, Wolint P, Zund G, Falk V, Zilla P, Hoerstrup SP: Injectable living marrow stromal cell-based autologous tissue engineered heart valves: First experiences with a one-step intervention in primates. Eur Heart J 2011;32:2830-2840.
84.
Baraki H, Tudorache I, Braun M, Hoffler K, Gorler A, Lichtenberg A, Bara C, Calistru A, Brandes G, Hewicker-Trautwein M, Hilfiker A, Haverich A, Cebotari S: Orthotopic replacement of the aortic valve with decellularized allograft in a sheep model. Biomaterials 2009;30:6240-6246.
85.
Iop L, Bonetti A, Naso F, Rizzo S, Cagnin S, Bianco R, Dal Lin C, Martini P, Poser H, Franci P, Lanfranchi G, Busetto R, Spina M, Basso C, Marchini M, Gandaglia A, Ortolani F, Gerosa G: Decellularized allogeneic heart valves demonstrate self-regeneration potential after a long-term preclinical evaluation. PLoS One 2014;9:e99593.
86.
Sievers H-H, Stierle U, Schmidtke C, Bechtel M: Decellularized pulmonary homograft (synergraft) for reconstruction of the right ventricular outflow tract: first clinical experience. Zeitschr Kardiol 2003;92:53-59.
87.
da Costa FD, Dohmen PM, Duarte D, von Glenn C, Lopes SV, Filho HH, da Costa MB, Konertz W: Immunological and echocardiographic evaluation of decellularized versus cryopreserved allografts during the ross operation. Eur J Cardiothorac Surg 2005;27:572-578.
88.
Zehr KJ, Yagubyan M, Connolly HM, Nelson SM, Schaff HV: Aortic root replacement with a novel decellularized cryopreserved aortic homograft: Postoperative immunoreactivity and early results. J Thor Cardiovasc Surg 2005;130:1010-1015.
89.
da Costa FDA, Costa ACBA, Prestes R, Domanski AC, Balbi EM, Ferreira ADA, Lopes SV: The early and midterm function of decellularized aortic valve allografts. Ann Thorac Surg 2010;90:1854-1860.
90.
Brown JW, Ruzmetov M, Eltayeb O, Rodefeld MD, Turrentine MW: Performance of synergraft decellularized pulmonary homograft in patients undergoing a ross procedure. Ann Thorac Surg 2011;91:416-423.
91.
Konertz W, Dohmen PM, Liu J, Beholz S, Dushe S, Posner S, Lembcke A, Erdbrügger W: Hemodynamic characteristics of the matrix p decellularized xenograft for pulmonary valve replacement during the ross operation. J Heart Valve Dis 2005;14:78-81.
92.
Konertz W, Angeli E, Tarusinov G, Christ T, Kroll J, Dohmen PM, Krogmann O, Franzbach B, Pace Napoleone C, Gargiulo G: Right ventricular outflow tract reconstruction with decellularized porcine xenografts in patients with congenital heart disease. J Heart Valve Dis 2011;20:341-347.
© 2016 S. Karger GmbH, Freiburg
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.